Hospital-based health technology assessment of innovative medical devices: insights from a nationwide survey in France
Fiche du document
2023
- handle: 10670/1.vlr9w6
- hal: hal-04229548
- doi: 10.1017/S0266462323000521
- PUBMED: 37732461
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1017/S0266462323000521
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/37732461
Sujets proches
Infirmaries Benevolent institutions Medical and sanitary affairs Hospitals, charities, etc Hospitals and sanitoriumsCiter ce document
Tess Martin et al., « Hospital-based health technology assessment of innovative medical devices: insights from a nationwide survey in France », HAL-SHS : économie et finance, ID : 10.1017/S0266462323000521
Métriques
Partage / Export
Résumé
Objectives To better understand the process of hospital acquisition of innovative medical devices (MDs) and the hospital-based health technology assessment (HB-HTA) pathways in France, an in-depth study based on a quantitative approach is needed. The aim of the present study was to assess through a national survey how HB-HTA is currently implemented in French hospitals and to identify its level of formalization. Methods A quantitative online survey was conducted among hospitals performing HB-HTA in France, with a focus on the acquisition of innovative MDs for individual use. The survey, conducted between March and June 2022, was developed by a scientific board composed of members of the French-speaking Society for HB-HTA. Results Sixty-seven out of 131 surveyed hospitals with HB-HTA activities responded, including 29 university hospitals, 24 nonprofit private hospitals, and 14 local hospitals. Sixty-one respondents (91 percent) reported the existence of a process dedicated to evaluating innovative MDs; of these, 16 declared that their hospitals had a formalized unit with HB-HTA activity. These units were more frequently found in larger hospitals with more than 500 inpatient beds (n = 16, p = 0.0160) and in university hospitals (n = 12, p = 0.0158). No hospital reported any collaboration with HAS, the French national HTA agency. Conclusion A diverse range of HB-HTA organizations with different structural levels exist in France for MD procurement linked to the category of hospitals. The study highlights the need for recognition of HB-HTA activity at the regulatory level in France and for direct collaboration between HTA activities performed at local and national levels.